Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Gregory A Otterson"'
Autor:
Natasha A Jain, Gregory A Otterson
Publikováno v:
Drugs in Context, Vol 8, Pp 1-6 (2019)
The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC). Concurrent chemoradiation with a platinum-based dou
Externí odkaz:
https://doaj.org/article/41224ba33ffd4c6fb7e22549dc23967e
Publikováno v:
Drugs in Context, Vol 8, Pp 1-5 (2019)
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends
Externí odkaz:
https://doaj.org/article/73fa62dbc7764aacb0af967e59ef5db3
Autor:
Eric D Miller, James L Fisher, Karl E Haglund, John C Grecula, Meng Xu-Welliver, Erin M Bertino, Kai He, Peter G Shields, David P Carbone, Terence M Williams, Gregory A Otterson, Jose G Bazan
Publikováno v:
Radiation Oncology, Vol 13, Iss 1, Pp 1-10 (2018)
Abstract Background To compare patterns of care for elderly patients versus non-elderly patients with non-surgically treated stage III non-small cell lung cancer (NSCLC) using the National Cancer Database (NCDB). We hypothesize that elderly patients
Externí odkaz:
https://doaj.org/article/f2a836765e9b414ba53a6bf53cdae1cf
Autor:
Wenrui eDuan, Li eGao, Brittany eAguila, Arjun eKalvala, Gregory A Otterson, Miguel Angel Villalona
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
The Fanconi Anemia (FA) pathway is a major mechanism of homologous recombination DNA repair. The functional readout of the pathway is activation through mono-ubiquitination of FANCD2 leading to nuclear foci of repair. We have recently developed an FA
Externí odkaz:
https://doaj.org/article/b3aef912cde34fc39baa2b15a9ff40c1
Autor:
Lisandra West, Smruti J Vidwans, Nicholas P Campbell, Jeff Shrager, George R Simon, Raphael Bueno, Phillip A Dennis, Gregory A Otterson, Ravi Salgia
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31906 (2012)
The remarkably heterogeneous nature of lung cancer has become more apparent over the last decade. In general, advanced lung cancer is an aggressive malignancy with a poor prognosis. The discovery of multiple molecular mechanisms underlying the develo
Externí odkaz:
https://doaj.org/article/72f54aabe8694c72a1b5dc86b9ee450e
Autor:
Wenrui Duan, Li Gao, Xin Wu, Erinn M Hade, Jian-Xin Gao, Haiming Ding, Sanford H Barsky, Gregory A Otterson, Miguel A Villalona-Calero
Publikováno v:
PLoS ONE, Vol 4, Iss 5, p e5563 (2009)
BACKGROUND:Mutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon 273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites. METHODOLOGY:To investigate the role of mutan
Externí odkaz:
https://doaj.org/article/f7637b01c18f460da08e806bf873df30
Autor:
Guolin Chai, Lian Li, Wen Zhou, Lipeng Wu, Ying Zhao, Donglai Wang, Shaoli Lu, Yu Yu, Haiying Wang, Michael A McNutt, Ye-Guang Hu, Yingqi Chen, Yang Yang, Xin Wu, Gregory A Otterson, Wei-Guo Zhu
Publikováno v:
PLoS ONE, Vol 3, Iss 6, p e2445 (2008)
5-Aza-2'-deoxycytidine (5-aza-CdR) is used extensively as a demethylating agent and acts in concert with histone deacetylase inhibitors (HDACI) to induce apoptosis or inhibition of cell proliferation in human cancer cells. Whether the action of 5-aza
Externí odkaz:
https://doaj.org/article/bb0948831c134fafa74209741842ac68
Autor:
Romulo M Brena, Carl Morrison, Sandya Liyanarachchi, David Jarjoura, Ramana V Davuluri, Gregory A Otterson, David Reisman, Selina Glaros, Laura J Rush, Christoph Plass
Publikováno v:
PLoS Medicine, Vol 4, Iss 3, p e108 (2007)
BackgroundLung cancer is the leading cause of cancer-related death worldwide. Currently, tumor, node, metastasis (TNM) staging provides the most accurate prognostic parameter for patients with non-small cell lung cancer (NSCLC). However, the overall
Externí odkaz:
https://doaj.org/article/8570a3421c7e4beb982ab6d4910b8dad
Autor:
Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga, Kristin L. Koenig
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its intravenous formulati
Externí odkaz:
https://doaj.org/article/8ad7f046ca434399a6659ce354285d41
Autor:
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100332- (2022)
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer fo
Externí odkaz:
https://doaj.org/article/46b674c9f39d4db4b8d61e682c4faee9